$0.98
+0.02 (+2.42%)
Open$0.98
Previous Close$0.96
Day High$0.99
Day Low$0.95
52W High$2.64
52W Low$0.50
Volume—
Avg Volume92.6K
Market Cap42.97M
P/E Ratio0.86
EPS$1.16
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,030.1% upside
Current
$0.98
$0.98
Target
$11.07
$11.07
$6.75
$11.07 avg
$12.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.77M | 20.27M | 7.77M |
| Net Income | 55.43M | 79.20M | 1.80M |
| Profit Margin | 434.2% | 412.5% | 23.2% |
| EBITDA | -25,054,024 | -37,785,875 | 2.38M |
| Free Cash Flow | — | — | 1.78M |
| Rev Growth | -37.0% | -37.0% | +3.8% |
| Debt/Equity | — | — | 0.84 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |